Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

ADVERTISEMENT

Molnupiravir becomes the first Oral Antiviral Drug to be included in WHO’s living Guidelines on COVID-19 Therapeutics 

WHO has updated its living guidelines on COVID-19 therapeutics. The ninth update released on 03 March 2022 include a conditional recommendation on molnupiravir. 

Molnupiravir has become the first oral antiviral drug to be included in the treatment guidelines for COVID-19. As this is a new medicine, there is little safety data. Therefore, WHO recommends, molnupiravir should be given only to non-severe COVID-19 patients with the highest risk of hospitalization such as older people, people with immunodeficiencies and people living with chronic diseases.  

No recommendation was made in patients with severe or critical illness as there are no trial data on molnupiravir for this population. 

Children, and pregnant and breastfeeding women should not be given the drug.  

This recommendation on conditional use of molnupiravir is based on new data from six randomized controlled trials involving 4796 patients. This is the largest dataset on this drug so far. 

Molnupiravir is not widely available but steps have been taken towards increasing access, including the signing of a voluntary licensing agreement. 

  *** 

References:  

  1. WHO 2022. News release – WHO updates its treatment guidelines to include molnupiravir. 3 March 2022. Available at https://www.who.int/news/item/03-03-2022-molnupiravir  
  1. Practice Rapid Recommendations: A living WHO guideline on drugs for covid-19. Originally published 04 September 2020. updated 3 March 2022. BMJ 2020; 370 DOI: https://doi.org/10.1136/bmj.m3379  

***  

SCIEU Team
SCIEU Teamhttps://www.scientificeuropean.co.uk
Scientific European® | SCIEU.com | Significant advances in science. Impact on humankind. Inspiring minds.

Subscribe to our newsletter

To be updated with all the latest news, offers and special announcements.

Most Popular Articles

LignoSat2 will be made of Magnolia wood

LignoSat2, the first wooden artificial satellite developed by Kyoto University’s...

Spinal Cord Injury (SCI): Exploiting Bio-active Scaffolds to Restore Function

Self-assembled nanostructures formed using supramolecular polymers containing peptide amphiphiles (PAs) containing...

“Hearing Aid Feature” (HAF): The First OTC Hearing Aid Software receives FDA Authorisation 

“Hearing Aid Feature” (HAF), the first OTC hearing aid...
- Advertisement -
93,054FansLike
46,057FollowersFollow
1,772FollowersFollow
30SubscribersSubscribe